This story originally ran on March 8.

By Adam Bonislawski

Waters said this week that its ongoing patent dispute with PerkinElmer would not affect its ability to supply its mass spec customers.

However, past requests by Waters to reexamine the patents in question could suggest that it was concerned that it might infringe them, Theodore Naccarella, a patent attorney and partner in the law firm Saul Ewing LLP, told ProteoMonitor this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.